211 related articles for article (PubMed ID: 29039591)
1. Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease.
Burger MC; Ronellenfitsch MW; Lorenz NI; Wagner M; Voss M; Capper D; Tzaridis T; Herrlinger U; Steinbach JP; Stoffels G; Langen KJ; Brandts C; Senft C; Harter PN; Bähr O
Oncol Rep; 2017 Dec; 38(6):3291-3296. PubMed ID: 29039591
[TBL] [Abstract][Full Text] [Related]
2. Personalized Treatment for a Patient With a BRAF V600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From Ganglioglioma.
Meletath SK; Pavlick D; Brennan T; Hamilton R; Chmielecki J; Elvin JA; Palma N; Ross JS; Miller VA; Stephens PJ; Snipes G; Rajaram V; Ali SM; Melguizo-Gavilanes I
J Natl Compr Canc Netw; 2016 Nov; 14(11):1345-1350. PubMed ID: 27799506
[TBL] [Abstract][Full Text] [Related]
3. Dabrafenib plus trametinib in patients with BRAF
Wen PY; Stein A; van den Bent M; De Greve J; Wick A; de Vos FYFL; von Bubnoff N; van Linde ME; Lai A; Prager GW; Campone M; Fasolo A; Lopez-Martin JA; Kim TM; Mason WP; Hofheinz RD; Blay JY; Cho DC; Gazzah A; Pouessel D; Yachnin J; Boran A; Burgess P; Ilankumaran P; Gasal E; Subbiah V
Lancet Oncol; 2022 Jan; 23(1):53-64. PubMed ID: 34838156
[TBL] [Abstract][Full Text] [Related]
4. Dabrafenib and trametinib in BRAFV600E mutated glioma.
Brown NF; Carter T; Kitchen N; Mulholland P
CNS Oncol; 2017 Oct; 6(4):291-296. PubMed ID: 28984141
[TBL] [Abstract][Full Text] [Related]
5. Primary Meningeal Pleomorphic Xanthoastrocytoma With Anaplastic Features: A Report of 2 Cases, One With BRAF(V600E) Mutation and Clinical Response to the BRAF Inhibitor Dabrafenib.
Usubalieva A; Pierson CR; Kavran CA; Huntoon K; Kryvenko ON; Mayer TG; Zhao W; Rock J; Ammirati M; Puduvalli VK; Lehman NL
J Neuropathol Exp Neurol; 2015 Oct; 74(10):960-9. PubMed ID: 26352988
[TBL] [Abstract][Full Text] [Related]
6. Dabrafenib Treatment in a Patient with an Epithelioid Glioblastoma and BRAF V600E Mutation.
Ceccon G; Werner JM; Dunkl V; Tscherpel C; Stoffels G; Brunn A; Deckert M; Fink GR; Galldiks N
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29621181
[TBL] [Abstract][Full Text] [Related]
7. Rapid Clinical and Radiographic Response With Combined Dabrafenib and Trametinib in Adults With
Johanns TM; Ferguson CJ; Grierson PM; Dahiya S; Ansstas G
J Natl Compr Canc Netw; 2018 Jan; 16(1):4-10. PubMed ID: 29295876
[No Abstract] [Full Text] [Related]
8. Leptomeningeal tumor response to combined MAPK/ERK inhibition in V600E-mutated gliomas despite undetectable CSF drug levels.
Hottinger AF; Bensaid D; De Micheli R; Moura B; Mokhtari K; Cardoso E; Idbaih A; Stupp R
Ann Oncol; 2019 Jan; 30(1):155-156. PubMed ID: 30346479
[No Abstract] [Full Text] [Related]
9. Disseminated glioneuronal tumors occurring in childhood: treatment outcomes and BRAF alterations including V600E mutation.
Dodgshun AJ; SantaCruz N; Hwang J; Ramkissoon SH; Malkin H; Bergthold G; Manley P; Chi S; MacGregor D; Goumnerova L; Sullivan M; Ligon K; Beroukhim R; Herrington B; Kieran MW; Hansford JR; Bandopadhayay P
J Neurooncol; 2016 Jun; 128(2):293-302. PubMed ID: 26994902
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Dabrafenib in Pediatric Patients with
Hargrave DR; Bouffet E; Tabori U; Broniscer A; Cohen KJ; Hansford JR; Geoerger B; Hingorani P; Dunkel IJ; Russo MW; Tseng L; Dasgupta K; Gasal E; Whitlock JA; Kieran MW
Clin Cancer Res; 2019 Dec; 25(24):7303-7311. PubMed ID: 31811016
[TBL] [Abstract][Full Text] [Related]
11. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF
Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B
Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064
[TBL] [Abstract][Full Text] [Related]
12. Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.
Planchard D; Kim TM; Mazieres J; Quoix E; Riely G; Barlesi F; Souquet PJ; Smit EF; Groen HJ; Kelly RJ; Cho BC; Socinski MA; Pandite L; Nase C; Ma B; D'Amelio A; Mookerjee B; Curtis CM; Johnson BE
Lancet Oncol; 2016 May; 17(5):642-50. PubMed ID: 27080216
[TBL] [Abstract][Full Text] [Related]
13. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.
Ascierto PA; Minor D; Ribas A; Lebbe C; O'Hagan A; Arya N; Guckert M; Schadendorf D; Kefford RF; Grob JJ; Hamid O; Amaravadi R; Simeone E; Wilhelm T; Kim KB; Long GV; Martin AM; Mazumdar J; Goodman VL; Trefzer U
J Clin Oncol; 2013 Sep; 31(26):3205-11. PubMed ID: 23918947
[TBL] [Abstract][Full Text] [Related]
15. Dramatic clinical and radiographic response to BRAF inhibition in a patient with progressive disseminated optic pathway glioma refractory to MEK inhibition.
Bavle A; Jones J; Lin FY; Malphrus A; Adesina A; Su J
Pediatr Hematol Oncol; 2017 May; 34(4):254-259. PubMed ID: 29040023
[TBL] [Abstract][Full Text] [Related]
16. Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.
Brastianos PK; Shankar GM; Gill CM; Taylor-Weiner A; Nayyar N; Panka DJ; Sullivan RJ; Frederick DT; Abedalthagafi M; Jones PS; Dunn IF; Nahed BV; Romero JM; Louis DN; Getz G; Cahill DP; Santagata S; Curry WT; Barker FG
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26498373
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Dabrafenib for three children with brainstem BRAF
Philippe L; Maria K; Tariq A; Sofia M; Christine SM; Jean-Pierre F; Dudley RW; Sébastien P; Nada J; Valérie L
J Neurooncol; 2019 Oct; 145(1):135-141. PubMed ID: 31502039
[TBL] [Abstract][Full Text] [Related]
18. Combined therapy with dabrafenib and trametinib in BRAF-mutated metastatic melanoma in a real-life setting: the INT Milan experience.
Cavalieri S; Di Guardo L; Cimminiello C; Bono A; Tolomio E; Colombetti A; Valeri B; Di Tolla G; de Braud F; Del Vecchio M
Tumori; 2016 Oct; 102(5):501-507. PubMed ID: 27470608
[TBL] [Abstract][Full Text] [Related]
19. Recurrent ganglioglioma in adults treated with BRAF inhibitors.
Chamberlain MC
CNS Oncol; 2016; 5(1):27-9. PubMed ID: 26680369
[TBL] [Abstract][Full Text] [Related]
20. Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report.
Casadevall D; Vidal J; Gallardo F; Zuccarino F; Arumí-Uría M; Dalmases A; Bellosillo B; Montagut C
J Med Case Rep; 2016 Jun; 10(1):158. PubMed ID: 27255157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
